Harvard Bioscience (HBIO) Current Deferred Revenue (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Current Deferred Revenue of $3.7 million for Q1 2026, down 1.16% year-over-year from $3.7 million in Q1 2025, and up 0.58% quarter-over-quarter from $3.6 million in Q4 2025.
Harvard Bioscience (HBIO) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Current Deferred Revenue for 17 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 1.16% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (down 1.16% YoY), while the FY2025 annual figure was $3.6 million, down 4.23% from the prior year.
- Current Deferred Revenue climbed to $3.7 million in Q1 2026 per HBIO's latest filing, from $3.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $4.5 million in Q4 2023 and bottomed at $3.1 million in Q2 2025.
- Historically, Current Deferred Revenue has averaged $3.8 million across 5 years, with a median of $3.7 million in 2025.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue surged 33.77% — and 2025, when it slipped 21.62%.
- Harvard Bioscience's Current Deferred Revenue stood at $3.4 million in 2022, then jumped by 33.77% to $4.5 million in 2023, then dropped by 15.57% to $3.8 million in 2024, then retreated by 4.23% to $3.6 million in 2025, then rose by 0.58% to $3.7 million in 2026.
- Business Quant data shows HBIO's Current Deferred Revenue at $3.7 million in Q1 2026, $3.6 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.74 Mn |
| Mar 31, 2026 | 3.67 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | 3.14 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 3.81 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 4.01 Mn |
| Mar 31, 2024 | 4.39 Mn |
| Dec 31, 2023 | 4.51 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 3.84 Mn |
| Mar 31, 2023 | 4.12 Mn |
| Dec 31, 2022 | 3.37 Mn |
| Sep 30, 2022 | 3.64 Mn |
| Jun 30, 2022 | 3.61 Mn |
| Mar 31, 2022 | 3.96 Mn |
| Dec 31, 2021 | 4.27 Mn |
| Sep 30, 2021 | 3.62 Mn |